Company Deep Dive
Business segments breakdown, earnings transcript analysis, management credibility scoring, competitive landscape, and scenario modelling.
AMANTA.NS
Strong BuyPremium GrowerAmanta Healthcare Limited · Healthcare · India · $83M · Avg Vol: $174K/d
COMPANY DESCRIPTION
Amanta Healthcare Limited operates as a pharmaceutical company engaged in developing, manufacturing and marketing a diverse range of sterile liquid products and parenteral products in Africa, Latin America, the United Kingdom, and internationally.
FINANCIAL SUMMARY (INR)
| Year | 2023 | 2024 | 2025 | 2026 | CAGR | TTM |
|---|---|---|---|---|---|---|
| Revenue | 2.6B | 2.8B | 2.7B | 2.8B | 3.3% | 2.9B |
| EPS (INR) | -0.54 | 0.94 | 2.70 | 4.33 | 115.1% | 3.77 |
| Shares | 38.8M | 38.8M | 38.8M | 38.8M | 0.0% | 38.8M |
| Debt | 2.1B | 2.0B | 1.9B | 2.4B | 4.5% | 2.4B |
| Equity | 628.8M | 662.9M | 963.9M | 2.2B | 51.9% | — |
| Op CF | 425.8M | 580.7M | 466.2M | 484.5M | 4.4% | 484.5M |
| Inv CF | -65.3M | -103.2M | -244.7M | -936.1M | — | — |
| Fin CF | -423.2M | -463.2M | -234.7M | 1.3B | — | — |
SCORE BREAKDOWN
FUNDAMENTALS
SECTOR PEERS
Closest peers in Healthcare, ranked by industry match, size, and score similarity. Cross-listings of AMANTA.NS are excluded.
| Ticker | Company | Mkt Cap | StockRank | Signal |
|---|---|---|---|---|
| AMANTA.NS | Amanta Healthcare Limited(you) | $83M | 81 | Strong Buy |
| VALIANTLAB.NS | Valiant Laboratories Limited | $65M | 83 | Strong Buy |
| AHCL.NS | Anlon Healthcare Limited | $88M | 90 | Strong Buy |
| WANBURY.NS | Wanbury Limited | $91M | 69 | Buy |
| ZIMLAB.NS | ZIM Laboratories Limited | $73M | 67 | Buy |
| ANUHPHR.NS | Anuh Pharma Limited | $101M | 94 | Strong Buy |
| ALBERTDAVD.NS | Albert David Limited | $51M | 93 | Strong Buy |
| WINDLAS.NS | Windlas Biotech Limited | $248M | 84 | Strong Buy |
| SAKAR.NS | Sakar Healthcare Limited | $268M | 79 | Buy |
| JAGSNPHARM.NS | Jagsonpal Pharmaceuticals Limited | $165M | 94 | Strong Buy |
Peer medians: ROE 11.9% · P/E 42.5x · Gross margin 59.4%